Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Myovant Sciences Ltd's Business Segments
Myovant Sciences Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 100
Regions Reported
-
Myovant Sciences Ltd does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product61.3%
- Orgovyx48.6%
- Collaboration Revenue29.2%
- Myfembree10.5%
- License5%
- License and Service4%
- Richter Product Supply and Royalties1.8%
- Richter Product Supply1.4%
- Product and Service, Other0.5%
- Ryeqo Royalties0.4%
- Accord Product Supply and Royalties0.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 61 | 61.3% |
| Orgovyx | $ 49 | 48.6% |
| Collaboration Revenue | $ 29 | 29.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
8 more categories available
Sign in to unlock the full Myovant Sciences Ltd dataset.
Description of Myovant Sciences Ltd
Myovant Sciences Ltd. is a United Kingdom-based pharmaceutical and healthcare company dedicated to developing and commercializing innovative medicines to improve the lives of women and men around the world. They focus on reproductive medicine, urology, and endocrinology, particularly on developing therapeutics which focus on hormonal conditions.
The company was founded in 2016 by Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd in order to combine Takeda's global resources and strategic focus on oncology with Roivant's expertise in a broad array of therapeutic areas. Since Roivant had a strong track record of bringing new drugs to market, Myovant Sciences was established to focus on developing and commercializing innovative medicines to address unmet needs in women's health and prostate cancer.
Their lead product candidate, Relugolix, is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which was developed to address unmet medical needs in women and men with hormone-related diseases. Relugolix is currently under review by regulatory authorities in the United States, Europe and Japan for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer.
Myovant Sciences is also focused on developing and commercializing other innovative treatments for women's health conditions, such as menorrhagia, polycystic ovary syndrome (PCOS), and breast cancer. Their product portfolio includes several potential therapies in various stages of development, such as MVT-602, a kisspeptin agonist for controlled ovarian hyperstimulation in patients undergoing in vitro fertilization, and MVT-605, an oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer.
Through a series of partnerships and collaborations, Myovant Sciences has established a strong global presence, with operations in the United States, Japan, and Switzerland, and a network of partners across Europe and Asia. Their collaborations include an ongoing partnership with Pfizer to develop a drug for the treatment of uterine fibroids, a co-development and commercialization agreement with Sumitomo Dainippon Pharma for relugolix in Japan, and a strategic partnership with AbbVie for up to $4 billion to develop and commercialize relugolix in other indications such as endometriosis and uterine fibroids.
In addition to developing innovative medicines, Myovant Sciences is committed to positively impacting the communities it serves. They have established programs such as the Inspire Scholarship, which provides financial assistance to women pursuing graduate education in science, technology, engineering or math (STEM) fields, and partnerships with organizations such as the Black Women's Health Initiative and the National Organization for Rare Disorders (NORD) to create greater awareness of rare diseases and support patient advocacy efforts.
Overall, Myovant Sciences is a well-established pharmaceutical company that is focused on developing innovative treatments for hormone-related diseases in women and men, and is committed to delivering value to its stakeholders through partnerships, collaborations, and socially responsible initiatives.
The company was founded in 2016 by Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd in order to combine Takeda's global resources and strategic focus on oncology with Roivant's expertise in a broad array of therapeutic areas. Since Roivant had a strong track record of bringing new drugs to market, Myovant Sciences was established to focus on developing and commercializing innovative medicines to address unmet needs in women's health and prostate cancer.
Their lead product candidate, Relugolix, is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which was developed to address unmet medical needs in women and men with hormone-related diseases. Relugolix is currently under review by regulatory authorities in the United States, Europe and Japan for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer.
Myovant Sciences is also focused on developing and commercializing other innovative treatments for women's health conditions, such as menorrhagia, polycystic ovary syndrome (PCOS), and breast cancer. Their product portfolio includes several potential therapies in various stages of development, such as MVT-602, a kisspeptin agonist for controlled ovarian hyperstimulation in patients undergoing in vitro fertilization, and MVT-605, an oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer.
Through a series of partnerships and collaborations, Myovant Sciences has established a strong global presence, with operations in the United States, Japan, and Switzerland, and a network of partners across Europe and Asia. Their collaborations include an ongoing partnership with Pfizer to develop a drug for the treatment of uterine fibroids, a co-development and commercialization agreement with Sumitomo Dainippon Pharma for relugolix in Japan, and a strategic partnership with AbbVie for up to $4 billion to develop and commercialize relugolix in other indications such as endometriosis and uterine fibroids.
In addition to developing innovative medicines, Myovant Sciences is committed to positively impacting the communities it serves. They have established programs such as the Inspire Scholarship, which provides financial assistance to women pursuing graduate education in science, technology, engineering or math (STEM) fields, and partnerships with organizations such as the Black Women's Health Initiative and the National Organization for Rare Disorders (NORD) to create greater awareness of rare diseases and support patient advocacy efforts.
Overall, Myovant Sciences is a well-established pharmaceutical company that is focused on developing innovative treatments for hormone-related diseases in women and men, and is committed to delivering value to its stakeholders through partnerships, collaborations, and socially responsible initiatives.
Myovant Sciences Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative therapies in two primary areas: women’s health and endocrine diseases. Below is an extensive overview of the segments, products, and services offered by Myovant Sciences:
Segments
1. Women’s Health:
- This segment is dedicated to addressing significant unmet medical needs in women’s reproductive health. Myovant aims to provide solutions for conditions such as:
- Uterine Fibroids: Noncancerous growths in the uterus that can cause a variety of symptoms, including heavy menstrual bleeding and pelvic pain.
- Endometriosis: A painful condition where tissue similar to the lining inside the uterus grows outside it, leading to severe discomfort and fertility issues.
- Ovarian Cancer: The development of cancerous cells in the ovaries, with a focus on therapies that can potentially improve outcomes for patients.
2. Endocrine Diseases:
- This segment focuses on therapies that affect the endocrine system, which is responsible for hormone production and regulation. Key areas of interest include:
- Prostate Cancer: A common cancer among men that can affect hormone levels and overall health. Myovant works on therapies that manage the disease and improve quality of life.
- Advanced Prostate Cancer: This encompasses prostate cancer that has spread beyond the prostate gland, necessitating more complex treatment approaches.
Products
1. Relugolix:
- Mechanism: A small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
- Indications: Currently under investigation in Phase III clinical trials for the treatment of:
- Uterine fibroids
- Endometriosis
- Prostate cancer
- Overview: By blocking GnRH receptor activity, Relugolix reduces the production of sex hormones, which can alleviate symptoms of hormone-dependent conditions.
2. Orlissa (elagolix):
- Mechanism: A selective estrogen receptor modulator (SERM).
- Indications: Approved for the management of moderate to severe pain associated with endometriosis.
- Overview: Orlissa provides a non-invasive option for managing pain associated with endometriosis by modulating estrogen activity in the body.
3. MVT-602:
- Mechanism: A novel, once-daily injectable peptide.
- Indications: Under development for the treatment of female infertility.
- Overview: MVT-602 aims to provide a targeted approach to enhancing fertility treatments, representing a significant advancement in this therapeutic area.
4. RVT-1601:
- Mechanism: An oral small molecule prostaglandin F2 alpha (PGF2A) receptor agonist.
- Indications: Under investigation for the treatment of uterine fibroids.
- Overview: By activating the PGF2A receptors, RVT-1601 is expected to help in reducing the size of fibroids and alleviating related symptoms.
Services
1. Clinical Trials:
- Myovant Sciences is committed to conducting robust clinical trials to assess the safety and efficacy of its drug candidates. With over 60 clinical trial sites across:
- The United States
- Canada
- Europe
- Asia
- These trials are integral to advancing their research and ensuring regulatory approval for new therapies.
2. Patient Access Programs:
- To facilitate access to their therapies, Myovant provides patient access programs that include:
- Financial Assistance: Support for eligible patients to help cover the costs of their medications.
- Reimbursement Support: Assistance with navigating insurance processes to ensure patients can obtain their prescriptions.
- Patient Advocacy: Resources and support for patients, helping them understand their treatment options and managing their health.
3. Medical Affairs:
- The medical affairs team at Myovant engages with healthcare professionals to provide essential information regarding their products. This includes:
- Medical Information and Education: Offering comprehensive resources to help providers understand the mechanisms, indications, and benefits of Myovant’s therapies.
- Scientific Exchange: Participating in discussions and collaborations to further the understanding and research of their innovative products.
In summary, Myovant Sciences Ltd aims to transform healthcare for women and patients with endocrine diseases through its focused therapeutic approaches, robust clinical development pipeline, and comprehensive patient support services.
Segments
1. Women’s Health:
- This segment is dedicated to addressing significant unmet medical needs in women’s reproductive health. Myovant aims to provide solutions for conditions such as:
- Uterine Fibroids: Noncancerous growths in the uterus that can cause a variety of symptoms, including heavy menstrual bleeding and pelvic pain.
- Endometriosis: A painful condition where tissue similar to the lining inside the uterus grows outside it, leading to severe discomfort and fertility issues.
- Ovarian Cancer: The development of cancerous cells in the ovaries, with a focus on therapies that can potentially improve outcomes for patients.
2. Endocrine Diseases:
- This segment focuses on therapies that affect the endocrine system, which is responsible for hormone production and regulation. Key areas of interest include:
- Prostate Cancer: A common cancer among men that can affect hormone levels and overall health. Myovant works on therapies that manage the disease and improve quality of life.
- Advanced Prostate Cancer: This encompasses prostate cancer that has spread beyond the prostate gland, necessitating more complex treatment approaches.
Products
1. Relugolix:
- Mechanism: A small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
- Indications: Currently under investigation in Phase III clinical trials for the treatment of:
- Uterine fibroids
- Endometriosis
- Prostate cancer
- Overview: By blocking GnRH receptor activity, Relugolix reduces the production of sex hormones, which can alleviate symptoms of hormone-dependent conditions.
2. Orlissa (elagolix):
- Mechanism: A selective estrogen receptor modulator (SERM).
- Indications: Approved for the management of moderate to severe pain associated with endometriosis.
- Overview: Orlissa provides a non-invasive option for managing pain associated with endometriosis by modulating estrogen activity in the body.
3. MVT-602:
- Mechanism: A novel, once-daily injectable peptide.
- Indications: Under development for the treatment of female infertility.
- Overview: MVT-602 aims to provide a targeted approach to enhancing fertility treatments, representing a significant advancement in this therapeutic area.
4. RVT-1601:
- Mechanism: An oral small molecule prostaglandin F2 alpha (PGF2A) receptor agonist.
- Indications: Under investigation for the treatment of uterine fibroids.
- Overview: By activating the PGF2A receptors, RVT-1601 is expected to help in reducing the size of fibroids and alleviating related symptoms.
Services
1. Clinical Trials:
- Myovant Sciences is committed to conducting robust clinical trials to assess the safety and efficacy of its drug candidates. With over 60 clinical trial sites across:
- The United States
- Canada
- Europe
- Asia
- These trials are integral to advancing their research and ensuring regulatory approval for new therapies.
2. Patient Access Programs:
- To facilitate access to their therapies, Myovant provides patient access programs that include:
- Financial Assistance: Support for eligible patients to help cover the costs of their medications.
- Reimbursement Support: Assistance with navigating insurance processes to ensure patients can obtain their prescriptions.
- Patient Advocacy: Resources and support for patients, helping them understand their treatment options and managing their health.
3. Medical Affairs:
- The medical affairs team at Myovant engages with healthcare professionals to provide essential information regarding their products. This includes:
- Medical Information and Education: Offering comprehensive resources to help providers understand the mechanisms, indications, and benefits of Myovant’s therapies.
- Scientific Exchange: Participating in discussions and collaborations to further the understanding and research of their innovative products.
In summary, Myovant Sciences Ltd aims to transform healthcare for women and patients with endocrine diseases through its focused therapeutic approaches, robust clinical development pipeline, and comprehensive patient support services.